Featured Research

from universities, journals, and other organizations

Emory Researchers Participate In INSPIRE Trial For Patients With Fatal Lung Disease

Date:
January 24, 2005
Source:
Emory University Woodruff Health Sciences Center
Summary:
Every breath soon turns into a struggle for people living with idiopathic pulmonary fibrosis (IPF). Lung transplantation has been the only definite treatment option for this progressive disease with no cure that eventually robs its victims of their ability to breathe. But researchers at the Emory Center for the Treatment and Study of Interstitial Lung Disease (Emory ILD Center) are participating in a multi-center study to help treat the disease or increase the average six-year survival time for IPF patients.

Every breath soon turns into a struggle for people living with idiopathic pulmonary fibrosis (IPF). Lung transplantation has been the only definite treatment option for this progressive disease with no cure that eventually robs its victims of their ability to breathe. But researchers at the Emory Center for the Treatment and Study of Interstitial Lung Disease (Emory ILD Center) are participating in a multi-center study to help treat the disease or increase the average six-year survival time for IPF patients.

The INSPIRE trial, being conducted in 70 centers in North America, Europe, and Canada, is testing the safety and efficacy of Actimmune (interferon gamma-1b), a disease-modifying drug with a low side effect profile. Interferon gamma-1b is a cytokine produced naturally by the body and has anti-fibrotic properties (i.e. helps prevent thickening or scarring of connective tissue). The phase three trial testing interferon gamma-1b is currently in the most advanced phase of a number of treatment options for IPF.

Jesse Roman, MD, is the director of the division of Pulmonary Allergy and Critical Care Medicine at Emory University, and director of the Emory ILD Center.

"We strive to provide patients and their physicians with advanced experimental treatment regimens and we're enthusiastic about discoveries that will allow us to develop new and better therapies for their lung condition," Dr. Roman says.

The INSPIRE trial is a phase three, randomized, double-blind, placebo-controlled study sponsored by InterMune, Inc. The trial is recruiting 600 IPF patients between the ages of 40 and 79 for a two-year evaluation period. Patients are randomized at a 2:1 ratio into a group receiving 200 mcg of interferon-gamma subcutaneously three times weekly for two years or into a group receiving placebo only. A physical examination, vital signs, electrocardiogram, hematology, urinalysis, and blood chemistry profiles will evaluate safety, and a high-resolution computerized tomography of the chest will be performed. Adverse events including infections and death will also be recorded. The primary efficacy outcome measure of the study will be survival time from date of randomization in patients diagnosed with IPF.

IPF is classified as an interstitial lung disease (ILD), a group of lung conditions that is characterized by a buildup of scar tissue in the lungs. The disease damages the air sacs of the lower respiratory tract as the scar tissue forms and thickens, causing an irreversible reduction of the transfer of oxygen to the bloodstream. Although no definite cause has been discovered, it is thought to be caused by injury or inflammation induced by an unknown agent. Pulmonary fibrosis is mostly attributed to inhaled environmental exposures, connective tissue, drug toxicity from chemotherapy radiation, diseases such as sclerodoma, lupus or sarcoidosis, and inherited causes.

Pulmonary hypertension and respiratory failure threaten the lives of IPF patients, Dr. Roman notes.

"Many patients are unable to perform their usual daily activities because of shortness of breath. Their lungs continue to deteriorate and soon they're also plagued with an unyielding dry cough and appetite loss," Dr. Roman says. "However we hope treatments that may be derived from studies like the INSPIRE trial will help improve their quality of life or ultimately successfully treat the disease."

According to the Coalition for Pulmonary Fibrosis, an estimated 31,000 new cases of IPF are diagnosed each year and approximately 83,000 Americans suffer from IPF. An estimated two-thirds of those patients die within five years of diagnosis.

Interested patients needing complete inclusion criteria for the clinical trial should contact the study coordinator Patricia Alvarez, MD at (404) 727-6821.


Story Source:

The above story is based on materials provided by Emory University Woodruff Health Sciences Center. Note: Materials may be edited for content and length.


Cite This Page:

Emory University Woodruff Health Sciences Center. "Emory Researchers Participate In INSPIRE Trial For Patients With Fatal Lung Disease." ScienceDaily. ScienceDaily, 24 January 2005. <www.sciencedaily.com/releases/2005/01/050121111825.htm>.
Emory University Woodruff Health Sciences Center. (2005, January 24). Emory Researchers Participate In INSPIRE Trial For Patients With Fatal Lung Disease. ScienceDaily. Retrieved October 20, 2014 from www.sciencedaily.com/releases/2005/01/050121111825.htm
Emory University Woodruff Health Sciences Center. "Emory Researchers Participate In INSPIRE Trial For Patients With Fatal Lung Disease." ScienceDaily. www.sciencedaily.com/releases/2005/01/050121111825.htm (accessed October 20, 2014).

Share This



More Health & Medicine News

Monday, October 20, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Microneedle Patch Promises Painless Pricks

Microneedle Patch Promises Painless Pricks

Reuters - Innovations Video Online (Oct. 18, 2014) Researchers at The National University of Singapore have invented a new microneedle patch that could offer a faster and less painful delivery of drugs such as insulin and painkillers. Video provided by Reuters
Powered by NewsLook.com
Raw: Nurse Nina Pham Arrives in Maryland

Raw: Nurse Nina Pham Arrives in Maryland

AP (Oct. 17, 2014) The first nurse to be diagnosed with Ebola at a Dallas hospital walked down the stairs of an executive jet into an ambulance at an airport in Frederick, Maryland, on Thursday. Pham will be treated at the National Institutes of Health. (Oct. 16) Video provided by AP
Powered by NewsLook.com
Raw: Cruise Ship Returns to US Over Ebola Fears

Raw: Cruise Ship Returns to US Over Ebola Fears

AP (Oct. 17, 2014) A Caribbean cruise ship carrying a Dallas health care worker who is being monitored for signs of the Ebola virus is heading back to Texas, US, after being refused permission to dock in Cozumel, Mexico. (Oct. 17) Video provided by AP
Powered by NewsLook.com
Spanish Govt: Four Suspected Ebola Cases in Spain Test Negative

Spanish Govt: Four Suspected Ebola Cases in Spain Test Negative

AFP (Oct. 17, 2014) All four suspected Ebola cases admitted to hospitals in Spain on Thursday have tested negative for the deadly virus in a first round of tests, the government said Friday. Duration: 00:55 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins